Geron (NASDAQ:GERN) Share Price Crosses Above 200-Day Moving Average of $1.27

Geron Co. (NASDAQ:GERNGet Rating) passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.27 and traded as high as $1.30. Geron shares last traded at $1.19, with a volume of 2,967,414 shares changing hands.

A number of research analysts have commented on the company. StockNews.com assumed coverage on Geron in a report on Thursday, March 31st. They issued a “sell” rating on the stock. B. Riley reaffirmed a “buy” rating on shares of Geron in a report on Friday, March 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Geron in a report on Friday, March 11th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Geron has an average rating of “Buy” and a consensus price target of $5.50.

The business has a 50-day moving average price of $1.40 and a two-hundred day moving average price of $1.27. The stock has a market capitalization of $449.16 million, a P/E ratio of -3.31 and a beta of 0.99. The company has a current ratio of 3.77, a quick ratio of 3.77 and a debt-to-equity ratio of 0.51.

Geron (NASDAQ:GERNGet Rating) last released its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.10 million. Geron had a negative return on equity of 85.84% and a negative net margin of 8,584.92%. During the same period in the prior year, the company posted ($0.09) EPS. On average, sell-side analysts forecast that Geron Co. will post -0.37 earnings per share for the current fiscal year.

Several large investors have recently added to or reduced their stakes in the company. Rafferty Asset Management LLC lifted its position in shares of Geron by 46.1% during the 4th quarter. Rafferty Asset Management LLC now owns 569,308 shares of the biopharmaceutical company’s stock worth $695,000 after buying an additional 179,553 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its position in shares of Geron by 26.1% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 55,622 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 11,507 shares during the last quarter. Wedbush Securities Inc. lifted its position in shares of Geron by 90.8% during the 4th quarter. Wedbush Securities Inc. now owns 25,000 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 11,900 shares during the last quarter. Arnhold LLC lifted its position in shares of Geron by 69.7% during the 1st quarter. Arnhold LLC now owns 142,400 shares of the biopharmaceutical company’s stock worth $194,000 after buying an additional 58,500 shares during the last quarter. Finally, Summit X LLC lifted its position in shares of Geron by 27.9% during the 1st quarter. Summit X LLC now owns 91,165 shares of the biopharmaceutical company’s stock worth $123,000 after buying an additional 19,868 shares during the last quarter. Hedge funds and other institutional investors own 47.75% of the company’s stock.

About Geron (NASDAQ:GERN)

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

Read More

Want More Great Investing Ideas?

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.